Parietaria sublingual allergoid immunotherapy with a co-seasonal treatment schedule

Allergologia et Immunopathologia

Volumn 36, Issue 2, 2008, Pages 79-84

  D'Anneo, R W ^a   Arena, A ^b   Gammeri, E ^b   Bruno, Marco E ^c   Falagiani, P ^c   Riva, G ^c   Leonardi, S ^d   La Rosa, M ^d  

^a Papardo Hospital   (Italy)

^b ASL 5   (Italy)

^c Lofarma SpA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Asthma; Bronchial reactivity; Carbamylated allergoid; Methacholine; Rhinitis; Sublingual immunotherapy

Indexed keywords

ALLERGOID; ANTIHISTAMINIC AGENT; BRONCHODILATING AGENT; IMMUNOMODULATING AGENT; METHACHOLINE;

ADULT; ARTICLE; ASPERGILLUS; ASTHMA; CONTROLLED STUDY; DERMATOPHAGOIDES; DRUG SAFETY; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PARIETARIA; RHINITIS; SKIN TEST; VISUAL ANALOG SCALE;

EID: 45549106342     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1157/13120392     Document Type: Article

References (14)

1. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629-32.
2. Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy 2001;56:989-92.
3. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999; 54:1110-3.
4. Rossi RE, Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005;18:277-85.
5. Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann P, Ruffin P et al. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 2002;129:248-53.
6. Passalacqua G, Lombardi C, Guerra L, Compalati E, Fumagalli F, Canonica GW. Sublingual immunotherapy: no more doubts. Eur Ann Allergy Clin Immunol 2005;37:314-20.
7. Giordano T, Quarta C, Bruno ME, Falagiani P, Riva G. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase. Eur Ann Allergy Clin Immunol 2006;9:310-2.
8. Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P. Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 1996; 51:8-15.
9. La Grutta S, Arena A, D'Anneo WR, Gammeri E, Leonardi S, Trimarchi A, et al. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamilated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled trial. Eur Ann Allergy Clin Immunol 2007; 39:40-4.
10. Gammeri E, Arena A, D'Anneo R, La Grutta S. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol 2005;33:142-4.
11. Durham SR, Yang WH, Pedersen MR, Johansen N, Eng Msc-C, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-9.
12. Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-γ- and interleukin-10-production. Clin Exp Allergy 2006;36:261-72.
13. Calderon M, Essendrop M. Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. J Invest Clin Immunol 2006;16:338-44.
14. Capperucci C, De Nuntiis P. La rete di monitoraggio nel 2006 tra tradizione e nuove prospettive. Not Allergol 2006;25:83-8.